GlassScriptPhysician profile
Samuel Ross Birer
NPI 1679004014
$1,883.12
in general payments reported to CMS, 2019-2025
27 companies · $314 in 2025
The $314 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $160 · 2023: $797 · 2024: $613 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,667 · Education: $55.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,667.23 |
| Education | $55.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $295.63 | 2023-2025 | Imfinzi |
| Regeneron Healthcare Solutions, INC. | $278.82 | 2022-2024 | Libtayo |
| Elekta, INC. | $210.62 | 2023 | Elekta Medical Linear Accelerator |
| Janssen Biotech, INC. | $143.06 | 2023-2024 | Erleada, Akeega |
| Janssen Scientific Affairs, LLC | $125.71 | 2024 | Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $100.97 | 2023-2025 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $97.11 | 2023-2025 | |
| Novocure INC. | $76.30 | 2023 | Optune |
| Merck Sharp & Dohme LLC | $72.95 | 2023-2024 | Keytruda, Welireg, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $71.82 | 2023-2024 | |
| Reflexion Medical, INC. | $41.03 | 2023 | Reflexion Medical Radiotherapy System |
| Abbvie INC. | $33.80 | 2025 | |
| Genmab U.S., INC. | $33.78 | 2025 | Epkinly |
| Fresenius Kabi USA, LLC | $32.24 | 2023 | Stimufend |
| Visionrt, INC. | $26.56 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $25.44 | 2025 | Onivyde |
| Eisai INC. | $25.33 | 2025 | |
| Servier Pharmaceuticals LLC | $23.28 | 2024 | |
| Genentech USA, INC. | $23.14 | 2025 | Polivy |
| Pfizer INC. | $21.42 | 2022 | |
| Impedimed, INC. | $20.15 | 2025 | |
| Genzyme Corporation | $19.39 | 2025 | |
| Sobi, INC | $19.36 | 2025 | |
| Seagen INC. | $17.92 | 2023 | Tivdak |
| Iovance Biotherapeutics, INC. | $17.32 | 2025 | Amtagvi |
| Incyte Corporation | $15.11 | 2025 | Jakafi, Monjuvi, Zynyz |
| Siemens Medical Solutions USA, INC. | $14.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Birer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.